All News
#1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT
➡️n=290, randomised to PBO, 5/15/30mg gps
💥30mg group
📉 Rapid skin improvement @ Wk 2
➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004)
🛟Well tolerated
⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains
#ACR @RheumNow https://t.co/5GusMlVkQ4
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Exciting early data for new highly selective TYK2i zasocitinib
Improved PASI skin scores (though not as much as IL23i...)
Funky skin-related adverse events at higher doses, not sure what to make of that?
#ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh
Links:
Mike Putman EBRheum ( View Tweet)
T2T approaches in early PsA:
-STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injection) vs SoC (MTX25+80mg steroid injection)
-At week 12, 38% pts on SEC vs
17% on SoC achieved ACR50. Also did better on MDA & PASI.
-No significant… https://t.co/MflI3d0FqV https://t.co/RjnzeaTyQK
Links:
Adela Castro AdelaCastro222 ( View Tweet)
How do you treat a flare of SLE with steroids?
@RheumNow #ACR24
Eric Dein ericdeinmd ( View Tweet)
Petri: 5 mg prednisone or less is our standard for lupus control
EULAR 23 recs - early addition of immunosuppressant and/or biologics instead to prevent steroids
@RheumNow
#ACR24 @jhrheumatology https://t.co/jhxEeboPu5
Links:
Eric Dein ericdeinmd ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
New agent on the block: Bimekizumab IL-17A/F inhibitor
Promising clinical data in SpA - what about imaging findings?
Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over
@RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
At "Envisioning a Steroid Free Future" talk
Angelo Gaffo at the mic: "Are there any situations you would do induction therapy for AAV without steroid?"
John Stone: [pause] "No." 😄
#ACR24 @RheumNow
Mike Putman EBRheum ( View Tweet)
#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai
💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%)
⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai.
🔴Durable therapy ❓better outcomes
#ACR @RheumNow https://t.co/LfA3WygNVq
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Reset the bar for remission (off steroids)!! Session #17S19
3% higher risk of organ damage for each 1mg of pred
Remission possible in rheum with lower dose GC regimen and faster taper #GCStewardship
#ACR24 @RheumNow @BethIWallace
Jiha Lee JihaRheum ( View Tweet)
Single centre experience of belimumab at @GSTTnhs
@RheumNow #ACR24 https://t.co/c4jlEPRwen
Mrinalini Dey DrMiniDey ( View Tweet)
In case you needed more encouragement for recombinant zoster vaccination in RA patients:
it prevents herpes zoster episodes, in the real world.
RA pts in KP system
n=1926 vaccinated matched 1:3 with non-vaccinated
- HZ reduced 60%
- PHN reduced 88%
#ACR24 ABST0977 @RheumNow https://t.co/BryBrlv9K5
David Liew drdavidliew ( View Tweet)
Petri on Steroids in SLE
Steroid-related organ damage presents later
- organ damage is higher in African-Americans
Dose response for prednisone and CVD risk
Each 1 mg prednisone = 3% increase risk in organ damage!
#ACR24 @jhrheumatology
@RheumNow https://t.co/00S1mxrXJp
Links:
Eric Dein ericdeinmd ( View Tweet)
Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data
https://t.co/86J4HWKeIv
@RheumNow #ACR24 https://t.co/QYqj5rKHIH
Links:
Eric Dein ericdeinmd ( View Tweet)
A systematic review reveals significant sex-related differences in efficacy and safety outcomes in axial spondyloarthritis (axSpA) trials. Males show higher response rates to advanced therapies compared to females. Out of 79 RCTs, only a fraction reported sex-disaggregated data.… https://t.co/dkMRK4ZYHF
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Give a listen to my @RheumNow interview w Josh Hsieh, a rising star at #ACR24, who is presenting his first (of many) research project as a high school sophomore!
His work w @NamrataRheum explores what is known- & not yet known- for cancer survival in RA
https://t.co/boqwpP9CUK https://t.co/UQ37pyvZT6
Eric Dein ericdeinmd ( View Tweet)
Quaack etlal. PreCARA study (vs PARA, historical control). T2T in RA improves fertility - time to pregnancy 84 days vs 196 days. T2T strategy also led to less NSAIDs and prednisolone. @RheumNow #ACR24 Abstr#1647 #ACRbest https://t.co/vYCCUqpCLo https://t.co/PUHJOxgGbL
Links:
Richard Conway RichardPAConway ( View Tweet)
#2282
🔬 Personalised Approach to TNFi in RA
📊 N=50👇; 43 responders
🔑 Findings
💥TNFR2 rs1061622 polymorphism linked to TNFi response
💥 MR/RR alleles ⬆️ 10X odds non-response v. MM allele (OR = 10.1,p=0.04)
🎯Genotyping may guide personalized RA therapy.
#ACR24 @RheumNow https://t.co/MQKZUCEPxj
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#1330
🔬F-Calprotectin in Early RA
➡️ New-onset RA pts(n=104) had ⬆️ F-calprotectin vs controls(n=50)(71 v. 17µg/g; p<0.001)
🔑Higher F-calprotectin linked to ⬆️ DAS28 & NSAID use
⬇️levels @ 6 months Rx
❓Role of subclinical gut inflammation in early RA
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
GILZ is a negative regulator of the GC receptor, a potential steroid sparer target.
Dr. Miceli et al identified an E3 ligase of GILZ "E3-X" where deficiency leads to ⬆️ GILZ & ⬇️ inflammation.
More studies needed but a promising steroid sparer option.
@Rheumnow #ACR24 abs1646 https://t.co/GuVMkgOTXT
Links:
sheila RHEUMarampa ( View Tweet)